The Council for Scientific and Industrial Research (CSIR) has launched India’s first anti-diabetic ayurvedic drug for type two Diabetes mellitus. The drug BGR-34 is developed jointly by National Botanical ResearchInstitute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), the Lucknow-based research units of CSIR. While the modern diabetes drugs are known for side-effects and toxicity, BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs.

For the purpose of quality commercial production and extended distribution, AIMIL Pharmaceuticals (I) Ltds, known for its innovative Ayurvedic products, has been transferred the rights and technical knowhow to produce and market it for medical use. BGR-34 costs Rs 5 per tablet and is available at all major chemist counters in Kerala.

BGR-34 for Blood Glucost Regulator, containing 34 identified activephyto-constitutes from herbal resources. AIMIL pharmaceuticals already had one successful technological collaboration with Defence Research and Development Organisation for effective and safe treatment of leucoderma, still considered a big challenge.